C11100P

DMT-dC(bz) Pharmadite^®

• Synonim(y): DMT-dC(bz) Phosphoramidite, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxycytidine, 3′-[2-cyanoethyl N,N-?bis(1-methylethyl)phosphoramidite]
• Wzór empiryczny (zapis Hilla): C₄₆H₅₂N₅O₈P
• Masa cząsteczkowa: 833.91
• Numer MDL: MFCD00036315
• Kod UNSPSC: 12352200
• Identyfikator substancji w PubChem: 329774847
• NACRES: NA.51

Właściwości

• pochodzenie biologiczne: non-animal source (no BSE/TSE risk)
• Poziom jakości: 300
• typ: for DNA synthesis
• linia produktu: Proligo Reagents
• Próba: ≥99.5% (reversed phase HPLC); >99.5% (³¹P-NMR)
• Postać: powder or granules
• metody: oligo synthesis: suitable
• zanieczyszczenia: >= 170ppm, none detected (S/N <2.5); ≤0.1% P(III) 100-169ppm (³¹P-NMR); ≤0.1% single unspecified Imprity (reversed phase HPLC); ≤0.3% dC2 (reversed phase HPLC, DMT-dC(bz) cyanoethyl-H-posphonate); ≤0.3% dC3 (reversed phase HPLC, DMT-dC(bz) phosphoramidate); ≤0.3% dC5 (reversed phase HPLC, O3′-Benzoyl-O5′-DMT-dC(bz)); ≤0.30 wt. % water content (Karl Fischer); ≤0.5% P(V) -25-99ppm (³¹P-NMR); ≤3.0 wt. % residual solvent content
• kolor: white to off-white
• rozpuszczalność: soluble, clear
• przydatność: conforms to structure for H-NMR; conforms to structure for LC-MS
• profil nukleozydowy: base: deoxycytidine; base protecting group: benzoyl; 2' protecting group: none; 5' protecting group: DMT; deprotection: standard
• temp. przechowywania: 2-8°C
• ciąg SMILES: COc1ccc(cc1)C(OC[C@H]2O[C@H](C[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)N3C=CC(NC(=O)c4ccccc4)=NC3=O)(c5ccccc5)c6ccc(OC)cc6
• InChI: 1S/C46H52N5O8P/c1-32(2)51(33(3)4)60(57-29-13-27-47)59-40-30-43(50-28-26-42(49-45(50)53)48-44(52)34-14-9-7-10-15-34)58-41(40)31-56-46(35-16-11-8-12-17-35,36-18-22-38(54-5)23-19-36)37-20-24-39(55-6)25-21-37/h7-12,14-26,28,32-33,40-41,43H,13,29-31H2,1-6H3,(H,48,49,52,53)/t40-,41+,43+,60?/m0/s1
• Klucz InChI: PGTNFMKLGRFZDX-SALLYJDFSA-N

Opis

Opis ogólny

DMT-dC(bz) Pharmadite^® is a Pharmadite^® product line that represents a new class of standard protected DNA phosphoramidites designed with highly controlled impurity profiles and exceptional overall purity.Pharmadite phosphoramidites are characterized by their exceptional purity and well-defined impurity profile. In particular, they are essentially free fromcontaminants that interfere in coupling reactions, such as other nucleosidic or non-nucleosidic phosphoramidites (P(III)-contaminants). All remainingimpurities in Pharmadite phosphopramidites, if present, are identified, characterized, and quantified. The impact of any such defined impurities on the synthesis of oligonucleotides is well understood and has been shown to be insignificant.

Informacje prawne

Pharmadite is a registered trademark of Merck KGaA, Darmstadt, Germany

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 1
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable